Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine‐needle aspirates: A quality‐assurance metric for evaluating diagnostic performance in a cytopathology laboratory

2021 ◽  
Author(s):  
Hamza N. Gokozan ◽  
Thomas L. Dilcher ◽  
Susan A. Alperstein ◽  
Yuqing Qiu ◽  
Maria Mostyka ◽  
...  
2015 ◽  
Vol 143 (2) ◽  
pp. 193-200 ◽  
Author(s):  
Frank Schneider ◽  
Matthew A. Smith ◽  
Molly C. Lane ◽  
Liron Pantanowitz ◽  
Sanja Dacic ◽  
...  

2020 ◽  
Vol 37 (4) ◽  
pp. 174
Author(s):  
Radhika Srinivasan ◽  
Ojas Gupta ◽  
Upasana Gautam ◽  
Muralidaran Chandrasekhar ◽  
Arvind Rajwanshi ◽  
...  

2021 ◽  
pp. jclinpath-2021-207429
Author(s):  
Roberta Sgariglia ◽  
Mariantonia Nacchio ◽  
Ilaria Migliatico ◽  
Elena Vigliar ◽  
Umberto Malapelle ◽  
...  

AimsIn thyroid cytopathology, the undetermined diagnostic categories still pose diagnostic challenges. Although next-generation sequencing (NGS) is a promising technique for the molecular testing of thyroid fine-needle aspiration (FNA) specimens, access to such technology can be difficult because of its prohibitive cost and lack of reimbursement in countries with universal health coverage. To overcome these issues, we developed and validated a novel custom NGS panel, Nexthyro, specifically designed to target 264 clinically relevant mutations involved in thyroid tumourigenesis. Moreover, in this study, we compared its analytical performance with that of our previous molecular testing strategy.MethodsThe panel, which includes 15 genes (BRAF, EIF1AX, GNAS, HRAS, IDH1, KRAS, NF2, NRAS, PIK3CA, PPM1D, PTEN, RET, DICER1, CHEK2, TERT promoter), was validated with a cell-line derived reference standard and 72 FNA archival samples previously tested with the 7-gene test.ResultsNexthyro yielded 100% specificity and detected mutant alleles at levels as low as 2%. Moreover, in 5/72 (7%) FNAs, it detected more clinically relevant mutations in BRAF and RAS genes compared with the 7-gene test. Nexthyro also revealed better postsequencing metrics than the previously adopted commercial ‘generic’ NGS panel.ConclusionOur comparative analysis indicates that Nexthyro is a reliable NGS panel. The study also implies that a custom-based solution for routine thyroid FNA is sustainable at the local level, allowing patients with undetermined thyroid nodules affordable access to NGS.


2018 ◽  
Vol 46 (4) ◽  
pp. 320-325 ◽  
Author(s):  
Kristen L. Partyka ◽  
Melissa L. Randolph ◽  
Karen A. Lawrence ◽  
Harvey Cramer ◽  
Howard H. Wu

Tuberculosis ◽  
2014 ◽  
Vol 94 (5) ◽  
pp. 502-505 ◽  
Author(s):  
Fantahun Biadglegne ◽  
Andargachew Mulu ◽  
Arne C. Rodloff ◽  
Ulrich Sack

Sign in / Sign up

Export Citation Format

Share Document